RU2011113762A - Способы применения композиций с замедленным высвобождением аминопиридина - Google Patents

Способы применения композиций с замедленным высвобождением аминопиридина Download PDF

Info

Publication number
RU2011113762A
RU2011113762A RU2011113762/13A RU2011113762A RU2011113762A RU 2011113762 A RU2011113762 A RU 2011113762A RU 2011113762/13 A RU2011113762/13 A RU 2011113762/13A RU 2011113762 A RU2011113762 A RU 2011113762A RU 2011113762 A RU2011113762 A RU 2011113762A
Authority
RU
Russia
Prior art keywords
subject
aminopyridine
administering
composition containing
sustained release
Prior art date
Application number
RU2011113762/13A
Other languages
English (en)
Russian (ru)
Inventor
Эндрю Р. БЛАЙТ (US)
Эндрю Р. Блайт
Рон КОЭН (US)
Рон Коэн
Original Assignee
Акорда Терапьютикс, Инк. (Us)
Акорда Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41799491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2011113762(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Акорда Терапьютикс, Инк. (Us), Акорда Терапьютикс, Инк. filed Critical Акорда Терапьютикс, Инк. (Us)
Publication of RU2011113762A publication Critical patent/RU2011113762A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2011113762/13A 2008-09-10 2009-09-10 Способы применения композиций с замедленным высвобождением аминопиридина RU2011113762A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9579708P 2008-09-10 2008-09-10
US61/095,797 2008-09-10

Publications (1)

Publication Number Publication Date
RU2011113762A true RU2011113762A (ru) 2012-10-20

Family

ID=41799491

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011113762/13A RU2011113762A (ru) 2008-09-10 2009-09-10 Способы применения композиций с замедленным высвобождением аминопиридина

Country Status (15)

Country Link
US (3) US20100061935A1 (enExample)
EP (1) EP2343976A4 (enExample)
JP (1) JP2012502103A (enExample)
CN (1) CN101827522A (enExample)
AR (1) AR073573A1 (enExample)
AU (1) AU2009291781A1 (enExample)
BR (1) BRPI0903914A2 (enExample)
CA (1) CA2736381A1 (enExample)
CL (1) CL2009001841A1 (enExample)
PA (1) PA8841801A1 (enExample)
PE (1) PE20100264A1 (enExample)
RU (1) RU2011113762A (enExample)
TW (1) TW201010703A (enExample)
UY (1) UY32109A (enExample)
WO (1) WO2010030755A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2814492A1 (en) * 2012-02-13 2014-12-24 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
DE102012103179A1 (de) 2012-04-12 2013-10-17 Sieber Forming Solutions Gmbh Verfahren und Vorrichtung zur spanlosen Herstellung eines Außengewindes auf Werkstücken aus Metall
UY34896A (es) * 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
WO2014028387A1 (en) * 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
CN104091062A (zh) * 2014-07-03 2014-10-08 刘鸿 基于检验效能的诊断性试验Meta分析的方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200462B (enExample) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
AU2004260702A1 (en) * 2003-08-01 2005-02-10 Ability Biomedical Corporation Combination therapies for Multiple Sclerosis
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2006130726A2 (en) * 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
US20090150180A1 (en) * 2005-09-23 2009-06-11 Ron Cohen Method, apparatus and solftware for identifying responders in clinical environment

Also Published As

Publication number Publication date
PE20100264A1 (es) 2010-04-28
UY32109A (es) 2010-04-30
EP2343976A1 (en) 2011-07-20
CN101827522A (zh) 2010-09-08
US20100061935A1 (en) 2010-03-11
US20130330277A1 (en) 2013-12-12
AU2009291781A1 (en) 2010-03-18
JP2012502103A (ja) 2012-01-26
WO2010030755A1 (en) 2010-03-18
CA2736381A1 (en) 2010-03-18
AR073573A1 (es) 2010-11-17
CL2009001841A1 (es) 2011-02-18
TW201010703A (en) 2010-03-16
BRPI0903914A2 (pt) 2015-07-21
EP2343976A4 (en) 2011-12-14
US20130072527A1 (en) 2013-03-21
PA8841801A1 (es) 2010-06-28

Similar Documents

Publication Publication Date Title
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
MX2010005676A (es) Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
PH12020551205A1 (en) Fap inhibitors
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
MD20130095A2 (ro) Compuşi condensaţi de benzoxazepinone ca modulatori ai canalelor ionice
BRPI0507198A (pt) derivados de bisariluréia
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
SG10201405826RA (en) Inhibitors of influenza viruses replication
WO2007112000A3 (en) Treatment of pain
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
SG171649A1 (en) Dpp iv inhibitor formulations
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EA200801997A1 (ru) Новые соединения
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
MX352647B (es) Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140303